FDA Grant Fast Track Designation to Elan Corporation PLC (ELN)'s ELND005 for the Treatment of Neuropsychiatric Symptoms in Alzheimer’s Disease
7/17/2013 10:03:46 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
DUBLIN, Ireland--(BUSINESS WIRE)--Elan Corporation, plc (NYSE:ELN) announced today that the US Food and Drug Administration (FDA) has granted Fast Track Designation to its development program for ELND005 which was submitted for the treatment of Neuropsychiatric Symptoms (NPS) in Alzheimer’s disease (AD). The FDA concluded that the development program for ELND005 for the treatment of NPS in AD meets their criteria for Fast Track Designation.
Help employers find you! Check out all the jobs and post your resume.
comments powered by